Codice QR

Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide

Current standard adjuvant therapy of glioblastoma multiforme (GBM) using temozolomide (TMZ) frequently fails due to therapy resistance. Thus, novel therapeutic approaches are highly demanded. We tested the therapeutic efficacy of the second-generation XPO1 inhibitor Eltanexor using assays for cell v...

Descrizione completa

Salvato in:
Autori principali: Katharina Otte, Kai Zhao, Madita Braun, Andreas Neubauer, Hartmann Raifer, Frederik Helmprobst, Felipe Ovalle Barrera, Christopher Nimsky, Jörg W. Bartsch, Tillmann Rusch
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI AG 2022-08-01
Serie:Biomedicines
Soggetti:
GBM
Eltanexor
SINE
XPO1
temozolomide
radiosensitivity
Accesso online:https://www.mdpi.com/2227-9059/10/9/2145
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi